Safety comes before efficacy
Starting from toxicology, using AI to develop therapies across the neural and vascular axes — safer, and no less effective.
Founded in 2021, Future PharmaTech focuses on the body's two great axes of life — neural and vascular — using AI-driven drug discovery to develop safer, more precise therapies.
2021
Founded
2
Neural & vascular axes
Our proprietary Future-AI platform, combined with nanomedicine, integrates drug repurposing and mechanism simulation to deliver drugs precisely across the blood-brain barrier (BBB) — raising efficacy while reducing side effects — for hard-to-treat diseases such as vascular dementia (VD) and erectile dysfunction (ED).
Guided by the principle of "not changing the patient's lifestyle," we design therapies that balance efficacy and comfort. Our team unites senior experts in pharmaceutical R&D, AI, and operations, partnering with global institutions to shorten the development cycle to within five years.
Our philosophy
"Medicine is also poison — it can save or it can harm."
01
A reality few confront
This is the toxicologist's worldview. Our founder, Prof. Chao Ming-Wei, trained in pharmacology and toxicology, knows it firsthand: too many new drugs prove effective, only to fail at the end on safety — years of work stopped at the final gate.
02
Toxicology at the very front of selection
So we work in reverse. Safety is not a late-stage checkpoint; it is the judgment that decides, from the very first step, whether a candidate deserves to be selected at all.
03
Designing backward from disease pathology
We first define the pathological core of a disease, then design candidate regimens in reverse — searching the neural and vascular axes for multi-target regimens that improve cerebral blood flow, modulate the blood-brain barrier, and promote neural repair.
Only by truly understanding poison can we make truly safe medicine.
Let future medicine care for your future.
Future PharmaTech — a new key to health.
Core values
Innovation-driven
Daring to challenge convention, accelerating therapy design through innovative technology.
Collaboration
Integrating cross-disciplinary team resources to solve clinical needs together.
Safety first
Toxicology and safety assessment at the very front of drug selection, screening out high-risk candidates at the source.
Pursuit of excellence
Continuously improving clinical translation efficiency and therapeutic performance.
Core team
Founder & CTO
Prof. Chao Ming-Wei
U.S. toxicologist, PhD, DABT
Vice President
Chen Bo-Dong
Medical laboratory scientist